The American Thoracic Society and the Infectious Diseases Society of America have developed evidence-based guidelines for the therapy of hospitalized patients with community-acquired pneumonia (CAP). In an attempt to evaluate if the care provided to hospitalized patients with CAP is in compliance with the care recommended by national guidelines, an international network of investigators has been collecting data from 40 hospitals in 13 countries. The care provided in the following areas of antibiotic therapy was analyzed: empiric antibiotic therapy, timing of initial antibiotic therapy, and switch from intravenous to oral antibiotic therapy. Lack of compliance with national guidelines was identified in all areas of antibiotic therapy. Compliance at the local level can be improved with the implementation of a hospital-based pneumonia quality improvement team. Improving compliance with national guidelines recommendations will produce a beneficial effect in CAP clinical and economic outcomes.

Download full-text PDF

Source

Publication Analysis

Top Keywords

antibiotic therapy
24
hospitalized patients
12
national guidelines
12
therapy hospitalized
8
patients community-acquired
8
community-acquired pneumonia
8
care provided
8
areas antibiotic
8
compliance national
8
antibiotic
6

Similar Publications

Background: Current guidelines recommend empiric antibiotic therapy for patients who require hospitalization for community-acquired pneumonia (CAP). We sought to determine whether clinical, imaging or laboratory features in patients hospitalized for CAP in whom PCR is positive for a respiratory virus enable exclusion of bacterial coinfection so that antibiotics can be withheld.

Methods: For this prospective study, we selected patients in whom an etiologic diagnosis was likely to be reached, namely those who provided a high-quality sputum sample at or shortly after admission, and in whom PCR was done to test for a respiratory virus.

View Article and Find Full Text PDF

Background: The healthcare sector faces a growing threat from the rise of highly resistant microorganisms, particularly Methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Pseudomonas aeruginosa (MDR P. aeruginosa). Facing the challenge of antibiotic resistance, nanoparticles have surfaced as promising substitutes for antimicrobial therapy.

View Article and Find Full Text PDF

Factors related to the progression of chronic obstructive pulmonary disease: a retrospective case-control study.

BMC Pulm Med

January 2025

Department of Geriatrics, Harrison International Peace Hospital, Intersection of Renmin Road, Hongqi Street, Taocheng District, Hengshui City, Hebei Province, 053000, China.

Objectives: To explore the factors related to the progression of chronic obstructive pulmonary disease (COPD).

Methods: 80 COPD patients treated between January 2020 and December 2022. The patients' pulmonary functions at their first hospital admission were categorized into four groups: Grade I, Grade II, Grade III and Grade IV.

View Article and Find Full Text PDF

Gut microbiota protect against colorectal tumorigenesis through lncRNA Snhg9.

Dev Cell

December 2024

Zhejiang Provincial Key Laboratory of Pancreatic Disease of The First Affiliated Hospital, Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou 310029, Zhejiang, China; Cancer Center, Zhejiang University, Hangzhou 310029, Zhejiang, China; Institute of Fundamental and Transdisciplinary Research, Zhejiang University, Hangzhou 310029, Zhejiang, China. Electronic address:

The intestinal microbiota is a key environmental factor in the development of colorectal cancer (CRC). Here, we report that, in the context of mild colonic inflammation, the microbiota protects against colorectal tumorigenesis in mice. This protection is achieved by microbial suppression of the long non-coding RNA (lncRNA) Snhg9.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!